Join vibrant discussions at Consilium Seminars: every other Thursday at 5pm London time

To watch the recordings, please create an account or login

17.06.2021 Challenges of Conducting Clinical Trials in Preventive Medicine by Prof Peter Sasieni  Sign Up
01.07.2021 A genealogy of conflict of interest in medicine by Dr. Boris Hauray
08.07.2021 Realise Advocacy by Josie Godfrey and Lindsay Weaver  Sign Up
15.07.2021 Complex innovative trial designs: the good, the bad and the ugly by Dr François Maignen

Perils of Peer Review

14.01.2021 17:00

Dr. Lisa Hutchinson and Prof. John Hickman
Scientific and clinical research that undergoes independent scrutiny by other qualified experts, Peer Review, enhances the integrity, validity, significance and acceptability of the published literature. This process can often be biased, unaccountable, ignorant, and wrong. Lisa and John explore the merits and limitations of peer review, issues that threaten the overall reputation of science (such as misconduct, data fabrication and falsification), and highlight existing efforts to endorse ethical behaviour. They also provide some suggestions to improve the recognition and value that peer review deserves.

Watch video


Cancer care in the United States

11.02.2021 17:00

Mike Kolodziej, MD

Cancer care in the United States: the challenges of access and cost

The US healthcare payment and delivery system is the most complicated in the world, and this is magnified when one considers managing a complex illness like cancer.
This talk reviews how healthcare is paid for and how cancer care is delivered, as well as ongoing efforts to improve quality while controlling cost.

Watch video


Reading the literature with a critical eye

25.02.2021 17:00

Ian Tannock, MD, PhD

In a critical appraisal of trials for cancer Professor Tannock focuses on topics like inappropriate controls, endpoints (surrogates for survival that aren't), under-reporting of toxicity, clinical value as opposed to statistical significance, failure to evaluate quality of life in trials of palliative treatments, and biased reporting.

Watch video


EU Horizon Policy: Cancer


Professor Chomienne presents the mission-approach concept to research and innovation and the work of the Horizon Europe Cancer Mission Board to make conquering cancer a mission possible in the near future.

Read the report: Conquering cancer, mission possible | European Commission (europa.eu) 

Watch video


Liquid biopsies for detection of lung cancer

03.06.2021 17:00

Professor Caroline Dive CBE, PhD

The argument for prioritizing the earlier detection of lung cancer is clear and this is how we step-change patient outcomes. However, challenges of delivering effective screening are substantial and will be discussed.  Professor Dive outlines the approach being taken in Manchester, combining Low Dose CTC scans with blood sample collection within a community at high risk of developing lung cancer.  She presents early data on circulating tumour DNA and circulating tumour cells and an optimistic vision of the future that will require a multi-modal approach for both earlier detection and minimal residual disease monitoring thereafter to enable earlier interventions with high chance of cure.  

Watch video


Clinical Trials in Preventive Medicine


Prof Peter Sasieni

Preventive medicine is a proactive approach to minimise ill-health through primary prevention, early detection of disease and treatment of risk factors. Since the recipients of preventive medicine are generally healthy individuals, trials need to be extremely large and often require long follow-up. Additionally, since a relatively small proportion of those recruited will benefit, it is important to ensure that the benefits outweigh any harms of the intervention. In this talk I will consider designs for clinical trials in cancer screening and cancer chemoprevention. I will discuss the ethical and logistic issues raised and illustrate the different designs via major trials in these areas.

Roundtable:Public voice in healthcare

28.01.2021 17:00

In some sectors, such as energy, climate and transport, significant and quite radical changes in policy have been driven by the public, particularly the Green Movement. In healthcare, AIDS activists were able to make a difference but many other aspects of healthcare require urgent attention. Why is public voice in healthcare not gaining sufficient visibility, traction and power?

 Watch video

Roundtable: Academic publishing

11.03.2021 17:00

The academic publishing model has been called into question over the past years. Open science movements are growing, the internet is providing new opportunities for access and also breeding excessive volumes of pseudo-scientific content.

Currently, academic publishing is a multi-billion-dollar business, which has drawn understandable criticism. The process of publishing puts tremendous pressure on researchers, charges millions from universities, and increasingly allows the publication of poor-quality content.

Sci-hub launched by Alexandra Elbakyan broke the existing model – is this the first step to reforming access to knowledge? What should the future of scientific publishing look like? How can we enforce quality standards, enable peer review, encourage editorial practices and editorial roles, and how can the remit of research funding be better aligned within publishing?

Join Consilium’s 2nd roundtable to share your opinions and to continue the discussions started at our earlier seminar this year on the Perils of Peer Review.

Watch video

The challenge of rare diseases


Josie Godfrey

Research into rare diseases has led to more new treatments coming to market. Are the challenges for rare disease drug development and commercialisation really that different to those of more common conditions and do they still need to be accommodated by regulators, HTA bodies and payers? 
This talk considers what is, and is not special about rare diseases and how this may change in an increasingly data driven world. It will consider how collaborative approaches to evidence might help address these challenges. 

Watch video 


Metrics for evaluation of scientific output


Dr. David Colquhoun

The use of metrics to evaluate the quality of individual scientists has corrupted science.  David Colquhoun talks about some examples that show that metrics don't measure what they claim to do.  The movement for "responsible metrics" is well intentioned but doomed to failure. Metrics are produced for commercial profit. If we stop buying them, they'll vanish.

Watch video


Master Observational Trials:


Dr. Silvia Marsoni

Master Observational Trials: Precision oncology is a heated medical topic arousing contrasting partisanships. Advocates stress the tremendous advantages of tailoring treatments to specific cancer hallmarks. Critics point to its substantial irrelevance in ‘real-world’ patients. Most however would agree that the one‐drug/care‐fits‐all model is in need of an urgent and profound overhaul. I attempt to persuade the audience that the concept of precision oncology is a science-stitched coverlet large enough to cover both research and care. To illustrate and support this concept, I present some of the past and current efforts of my group, mostly in the field of colorectal cancer and specifically honing on the notion that avoiding useless treatments is as ‘precise’ as targeting a rare oncogene.

Watch video


A genealogy of conflict of interest in medicine


Dr. Boris Hauray

 London UK | Bethesda, MD USA | 501(c)3 registered